Lenalidomide Grindeks

Lenalidomide, the active ingredient in Lenalidomide Grindeks, is an immunomodulatory agent presented as a tablet for oral use. It treats multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomide Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies.

Multiple Myeloma: improves progression‑free survival and overall response in patients with relapsed or refractory disease. Myelodysplastic Syndromes: reduces transfusion dependence and improves blood counts in patients with del(5q) cytogenetic abnormality. Mantle Cell Lymphoma: contributes to disease control in relapsed or refractory cases when combined with other therapies.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness reported by many patients. - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools occurring during treatment. - Constipation: reduced bowel movements. - Rash: skin irritation or redness. - Neutropenia: lowered neutrophil count.

Serious or Rare Side Effects: - Thromboembolic events: deep‑vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly low neutrophil levels increasing infection risk. - Secondary primary malignancies: emergence of new cancers. - Stevens‑Johnson syndrome: severe skin reaction. - Hepatic toxicity: elevated liver enzymes or liver injury.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for known safety concerns.

Monitor blood counts: perform regular CBC to detect neutropenia or anemia. Assess thromboembolic risk: consider prophylactic anticoagulation in high‑risk patients. Avoid in pregnancy: teratogenic; ensure effective contraception. Renal impairment: adjust dose or avoid in severe renal dysfunction. Store at below 25°C: keep in the original pack, protect from moisture.

Lenalidomide can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce drug exposure. - Live vaccines: increased risk of infection due to immunomodulation. - Anticoagulants (warfarin): heightened bleeding risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma levels. - NSAIDs: potential additive renal toxicity. - P‑gp inhibitors (e.g., verapamil): may raise lenalidomide concentrations.